Medical News

Third Generation Targeted Therapy for ROS1-Positive NSCLC

15. 4. 2020 Source: Genetic Profile and Treatment of NSCLC

The potent third-generation tyrosine kinase inhibitor, lorlatinib, has shown activity in preclinical studies against nearly all known mutations in the ALK and ROS1 genes that lead to resistance to crizotinib treatment. Moreover, lorlatinib crosses the blood-brain barrier, offering hope for patients with CNS metastases. The results of a clinical evaluation of the efficacy and safety of lorlatinib in patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) were published in The Lancet Oncology.

Key Role of HRCT in Diagnosing Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis is often an unjustly overlooked disease. The truth is that it is a rare disease, but the prognosis for patients is very poor. To improve quality of life and chances of…

15. 4. 2020 Source: Pulmonary Fibrosis

Výběr inkontinenční pomůcky dle absorpce

The Choice of Incontinence Aids Matters −⁠ But How Not to Get Lost Among Them?

Despite significant advances in medicine, a large number of patients still struggle with incontinence, which limits their comfort and reduces their quality of life. If treatment options have been…

14. 4. 2020 Source: Incontinence

Prevalence of Diabetics Among Patients with COVID-19 and the Impact of DM on the Course of Infection

Italian authors published the results of a meta-analysis of studies at the end of March, assessing the prevalence of diabetes among individuals infected with SARS-CoV2 and the impact of diabetes on…

14. 4. 2020 Source: Modern Treatment of Diabetes

Idiopathic Pulmonary Fibrosis: Rare Disease with Severe Prognosis

Idiopathic pulmonary fibrosis (IPF) represents a diagnostic and therapeutic challenge. This rare diffuse primary fibroproliferative involvement of lung tissue is characterized by progressive…

14. 4. 2020 Source: Pulmonary Fibrosis

Impact of Empagliflozin on the Risk of Cardiovascular Death and Need for Hospitalization Due to Heart Failure

In the EMPA-REG OUTCOME study, empagliflozin reduced the risk of cardiovascular death and the number of hospitalizations due to heart failure in patients with type 2 diabetes (T2DM) who had confirmed...

10. 4. 2020 Source: Diabetes

Domestic application of biological asthma treatment improves quality of life and reduces doctor visits

The benefits of the possibility of home application of omalizumab, a monoclonal antibody indicated for patients with severe allergic asthma, are summarized by Dr. Jakub Novosad, Ph.D., from the…

9. 4. 2020 Source: Asthma under control

Comparison of Efficacy and Safety of Unsaponifiable Soy and Avocado Oil and Chondroitin Sulfate in the Treatment of Knee Osteoarthritis

Osteoarthritis is the most common joint disease in adult patients, with its prevalence increasing with age, and these issues most frequently affect the knee joint. In the treatment of knee…

8. 4. 2020 Source: Osteoarthritis Therapy

The Presence of COPD Worsens the Course of COVID-19 –⁠ Results of Epidemiological Studies

Among the at-risk populations during the current COVID-19 pandemic are older individuals and those suffering from chronic comorbidities. The presence of chronic obstructive pulmonary disease (COPD),…

8. 4. 2020 Source: Treatment of Asthma and COPD

Are All Patients Really Suitable for Thromboprophylaxis Treated This Way?

A study published this year aimed to assess how often the risk of VTE is assessed in routine clinical practice in internally ill patients, what proportion of patients are suitable for…

8. 4. 2020 Source: Thromboprophylaxis

1 … 150 151 152 153 154 … 164

Back Filter by speciality

Remove filters